

Taisho Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd.

Taisho and Chugai Terminate the Co-Marketing Agreement of Ediol[®], a Treatment for Osteoporosis

TOKYO, January 22, 2021 -- Taisho Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced termination of the agreement between both companies regarding co-marketing of Ediol[®] Capsules 0.5 µg and 0.75 µg (hereafter, “Ediol”), a treatment for osteoporosis for which Chugai has a marketing authorization.

In May 2008, both companies entered into an agreement for co-development and marketing of Ediol. They have co-marketed Ediol and engaged in providing information in Japan since the launch of the product in April 2011. However, they have decided to terminate the agreement regarding co-marketing, following discussions on future marketing policies.

As such, Taisho will stop marketing and providing information on Ediol on April 10, 2021, while Chugai will solely be responsible for these activities from April 11, 2021.

Taisho and Chugai will cooperate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.

Ediol[®] is a trademark of Chugai.